105 reports of this reaction
3.1% of all BENZALKONIUM CHLORIDE 0.13% reports
#10 most reported adverse reaction
JOINT SWELLING is the #10 most commonly reported adverse reaction for BENZALKONIUM CHLORIDE 0.13%, manufactured by Meijer, Inc.. There are 105 FDA adverse event reports linking BENZALKONIUM CHLORIDE 0.13% to JOINT SWELLING. This represents approximately 3.1% of all 3,369 adverse event reports for this drug.
Patients taking BENZALKONIUM CHLORIDE 0.13% who experience joint swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
JOINT SWELLING is moderately reported among BENZALKONIUM CHLORIDE 0.13% users, representing a notable but not dominant share of adverse events.
In addition to joint swelling, the following adverse reactions have been reported for BENZALKONIUM CHLORIDE 0.13%:
The following drugs have also been linked to joint swelling in FDA adverse event reports:
JOINT SWELLING has been reported as an adverse event in 105 FDA reports for BENZALKONIUM CHLORIDE 0.13%. This does not prove causation, but indicates an association observed in post-market surveillance data.
JOINT SWELLING accounts for approximately 3.1% of all adverse event reports for BENZALKONIUM CHLORIDE 0.13%, making it a notable side effect.
If you experience joint swelling while taking BENZALKONIUM CHLORIDE 0.13%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.